Trial

TrialWire delivers superior trial patient recruitment solutions based on highly sophisticated information technology (IT) all in one secure platform SAN ANTONIO, Dec. 8, 2022 /PRNewswire/ -- Based on its recent analysis of the clinical…

8 December 2022 Clinigen notes results from the MIROCALS trial investigating low dose Proleukin® (aldesleukin) in patients with amyotrophic lateral sclerosis Clinigen Limited (‘Clinigen’), the global pharmaceutical services company,…

Geneva, Switzerland, 8 December 2022 -- iOnctura SA a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, announces today the first patient has been…

RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided initial results from a 24 patient Phase 2 mechanism of action (MOA) trial…

SAN FRANCISCO, Dec. 6, 2022 /PRNewswire/ -- The diaTribe Foundation, Advanced Technologies & Treatments for Diabetes (ATTD), and the Time in Range Coalition announced today a new international consensus regarding continuous glucose…

LONDON--(BUSINESS WIRE)--Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, will present a “Trial in Progress” poster detailing the design of a…

Best of SABCS® News Highlights coverage will provide daily expert video summaries along with original presentation slides of the most significant breast cancer trials for oncologists worldwide. SAN ANTONIO, Dec. 1, 2022 /PRNewswire/ --…

The study found  Dia Free Juice effective in reducing Fasting Blood Sugar (FBS) and Post-Prandial Blood Sugar (PPBS) values by up to 30% within 3 Months of consumptionNEW DELHI, Nov. 30, 2022 /PRNewswire/ -- Kapiva, a homegrown Ayurveda…

VANCOUVER and MINNEAPOLIS, Nov. 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced an update on the COSIRA-II Clinical Trial (“Trial”) status. COSIRA-II is the…

CNM-Au8 demonstrated low contrast vision improvement and global neurological improvement (low contrast vision, cognition, upper extremity function, and walking speed) in stable MS patients as adjunct to background immunomodulating…